Sansure Biotech Inc
SSE:688289
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sansure Biotech Inc
Change in Working Capital
Sansure Biotech Inc
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sansure Biotech Inc
SSE:688289
|
Change in Working Capital
-¥970m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Change in Working Capital
-¥138.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
-86%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Change in Working Capital
-¥1.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Change in Working Capital
-¥2.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Change in Working Capital
-¥1.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-26%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Change in Working Capital
-¥1.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
Sansure Biotech Inc
Glance View
Nestled in the bustling hub of China's life sciences innovation, Sansure Biotech Inc. has emerged as a pivotal player in the biotechnology landscape. Founded with a vision to harness cutting-edge technology for health diagnostics, the company has developed a comprehensive suite of diagnostic products and solutions. At its core, Sansure specializes in the research, development, and commercialization of in-vitro diagnostic reagents and instruments. By leveraging its proprietary technologies, the company addresses pressing global health challenges with precision diagnostics that span infectious diseases, oncology, and genetic testing, among others. Its portfolio encompasses both equipment and consumables, offering end-to-end solutions that enable healthcare providers to deliver accurate and timely diagnoses. Sansure's business model is intricately woven into the fabric of both innovation and distribution. The company thrives by consistently innovating its product line to keep pace with global health demands while optimizing its production processes for scale and efficiency. Revenue streams flow from the sale of its diagnostic kits and instruments, which are widely adopted in hospitals, clinics, and laboratories. Collaborations with research institutions and healthcare bodies have further cemented its status as a trusted partner in public health. Through strategic partnerships and an expanding international footprint, Sansure has built a robust distribution network that ensures its technologies are accessible to a diverse market, thus driving its financial growth and solidifying its standing in the biotech industry.
See Also
What is Sansure Biotech Inc's Change in Working Capital?
Change in Working Capital
-970m
CNY
Based on the financial report for Dec 31, 2024, Sansure Biotech Inc's Change in Working Capital amounts to -970m CNY.
What is Sansure Biotech Inc's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-45%
Over the last year, the Change in Working Capital growth was -12%. The average annual Change in Working Capital growth rates for Sansure Biotech Inc have been -26% over the past three years , -45% over the past five years .